Current treatment approaches in CML

Current treatment approaches in CML

Bibliographic Details
Main Authors:	Fausto Castagnetti, Gabriele Gugliotta, Simona Soverini, Michele Baccarani, Gianantonio Rosti
Format:	Article
Language:	English
Published:	Wiley 2019-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000201

Similar Items

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
by: Manuela Mancini, et al.
Published: (2022-08-01)

S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS
by: M. Mancini, et al.
Published: (2022-06-01)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
by: Fausto Castagnetti, et al.
Published: (2021-03-01)

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
by: Simona Soverini, et al.
Published: (2020-11-01)

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
by: Miriam Iezza, et al.
Published: (2023-06-01)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.
by: Manuela Mancini, et al.
Published: (2015-01-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
by: Domenico Russo, et al.
Published: (2020-06-01)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
by: Massimo Breccia, et al.
Published: (2017-10-01)

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
by: M. Mancini, et al.
Published: (2019-05-01)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
by: Giorgina Specchia, et al.
Published: (2021-08-01)

Hybrid Dynamic CML with Modified Current Source (H-MDyCML): A Low-Power Dynamic MCML Style
by: Riya Jain, et al.
Published: (2021-01-01)

Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
by: Domenico Russo, et al.
Published: (2023-12-01)

The expanding CML treatment landscape: an introspective commentary
by: Jeffrey H. Lipton
Published: (2023-09-01)

Progress with interferon in CML--results of the MRC UK CML III study.
by: Shepherd, P, et al.
Published: (1996)

P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY
by: F. Castagnetti, et al.
Published: (2022-06-01)

International CML forum
by: A. G. Turkina
Published: (2022-11-01)

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
by: Anushka Walia, et al.
Published: (2023-03-01)

Tailored CML Treatment in Indonesia, Let’s See More
by: Shinta Oktya Wardhani
Published: (2023-11-01)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
by: Daniela Zizioli, et al.
Published: (2021-02-01)

Characterization of the function of Calmodulin-like(CML) 23 and CML24 in the arabidopsis thaliana circadian clock /
by: Nur Izzati Mohd. Noh, author, et al.
Published: (2014)

Molecular Pathogenesis and Treatment Strategies of Chronic Myeloid Leukemia (CML)
by: Rabia Khalid, et al.
Published: (2023-12-01)

Exploration of treatment‐free remission in CML, based on molecular monitoring
by: Zhao Zhang, et al.
Published: (2024-01-01)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)

CML treatment results in Slovenia in the era of tirozin kinaze inhibitors
by: Irena Preložnik Zupan, et al.
Published: (2012-12-01)

Dynamical Systems Properties of a Mathematical Model for the Treatment of CML
by: Urszula Ledzewicz, et al.
Published: (2016-10-01)

Comparison of the Transcriptomic Signatures in Pediatric and Adult CML
by: Minyoung Youn, et al.
Published: (2021-12-01)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
by: Camille C.B. Kockerols, et al.
Published: (2020-12-01)

CMLLite: a design philosophy for CML
by: Townsend Joe A, et al.
Published: (2011-10-01)

Characterization of the function of Calmodulin-like(CML) 23 and CML24 in the arabidopsis thaliana circadian clock [electronic resource] /
by: Nur Izzati Mohd. Noh, author
Published: (2014)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
by: Henrike Jacobi, et al.
Published: (2023-07-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-04-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-01-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Identifying regulators of chronic myeloid leukaemic (CML) stem cell quiescence and discovering effective novel therapies for CML relapse
by: Xu, Z
Published: (2022)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
by: Fabien Muselli, et al.
Published: (2021-04-01)

NGS in CML - New standard diagnostic procedure?
by: Susan Branford, et al.
Published: (2019-06-01)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
by: N. Bouayed Abdelmoula, et al.
Published: (2022-06-01)

CML ENGAGEMENT IN ENGLISH COMPETENCY FOR TVET EDUCATORS
by: Nor Yazi, Khamis, et al.
Published: (2024)

UNLEASHING THE POWER OF CML THE JOURNEY TO EKSA AWARD
by: Fathiah Izzati, Mohammad Fadzillah, et al.
Published: (2024)